Pharmaleaders TV
You are here:  / Indian News / World news / Shares in India’s Natco Pharma Ltd surge 6 percent after prospects for its generic version for Teva Pharmaceutical Industries’ billion dollar drug got a boost from a favourable US court ruling.

Shares in India’s Natco Pharma Ltd surge 6 percent after prospects for its generic version for Teva Pharmaceutical Industries’ billion dollar drug got a boost from a favourable US court ruling.

Shares in India’s Natco Pharma Ltd surge 6 percent after prospects for its generic version for Teva Pharmaceutical Industries’ billion dollar drug got a boost from a favourable US court ruling on Wednesday.

Shares in India's Natco Pharma Ltd surge 6 percent after prospects for its generic version for Teva Pharmaceutical Industries' billion dollar drug got a boost from a favourable US court ruling. Reuters

An US Supreme Court justice on Wednesday declined a request from Teva for a stay of an appeals court ruling that would strip the company’s $4 billion-a-year multiple sclerosis drug Copaxone of patent protection in 2014, rather than in 2015.

In July, the US Court of Appeals for the Federal Circuit issued a decision in a patent fight that pits Teva against two teams developing cheaper generic forms of Copaxone: one with Novartis AG and Momenta Pharmaceuticals Inc ; and another between Mylan Inc and Natco Pharma.

PHARMALEADERS

Pharmaleaders is India’s first opinion based & research driven bi-monthly magazine & has a decade of relentless reporting in Pharma Journalism in an unbiased, fearless & independent way. Over the last one decade, The Magazine has covered some of the biggest voices in the healthcare Industry. Available both in digital & printed format, Pharmaleaders has emerged out as a leading title in voicing the opinion of the healthcare industry.

Follow us
Contact us

Network 7 Meadia Group

Plot 5, NS Road No. 12, JVPD, Juhu Scheme, Mumbai, Maharashtra 400049. editorial@pharmaleaders.tv